After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
While overall survival data remain immature, the results pointed to a favourable trend.
With standout ADC and t-cell engager response data across hard-to-treat cancers
The standout story remains Wegovy, particularly its new oral formulation
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The company’s Growth Portfolio delivered $6.2 billion in revenue
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
